Gustave Roussy et FabRx Ltd, start-up de biotechnologie qui a lancé l'imprimante pharmaceutique 3D M3DIMAKER™, annoncent leur nouvelle collaboration de recherche. Leur partenariat consiste à développer des formes galéniques inédites, personnalisées combinant plusieurs principes actifs dans le cadre de la prise en charge de patientes atteintes d'un cancer du sein localisé.
Sanofi, Gustave Roussy, l’Inserm, l’Institut Polytechnique de Paris et l’Université Paris-Saclay s’engagent pour faire émerger en France une médecine personnalisée à travers un cluster en oncologie centré sur le patient : le Paris Saclay Cancer Cluster.
Gustave Roussy clinical research is organized to enhance its performance, to develop its ability to manage large national and international academic trials with high added value and to strengthen Gustave Roussy position as a preferred innovative trials platform for pharma companies.
As an Investigator site, Gustave Roussy has a Clinical Operations Unit ensuring clinical research activities for all therapeutic trials and clinical studies. This service is provided regardless of the sponsor category (pharma industries, biotech, scientific associations, academic institutions), at all development phases (from early to advanced phase) including strategic areas such as Molecular Medicine, Antitumor Immunology, DNA repair and rare Cancers.
The international meeting of the American Society of Clinical Oncology (ASCO) gathers every year the world’s leading cancer experts. In 2021, ASCO meeting is virtual. Oral, Poster Discussion, and Poster Sessions, as well as track-based Clinical Science Symposia, are available on ASCO's website.